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Abstract
Background: Adherence to medication is one of the critical determinants of successful management of chronic
diseases including asthma and chronic obstructive pulmonary disease (COPD). Given that poor adherence with
self-management medication is very common among asthma and COPD patients, interventions that improve the
use of chronic disease management medications for this patient group have potential to generate positive
health outcomes. In an effort to improve asthma and COPD care, the Lung Association of Saskatchewan has
implemented an intervention by providing access to effective and high quality asthma and COPD education for
both patients and health care professionals along with increasing access to spirometry.
By evaluating the impacts of this intervention, our purpose in this paper is to examine the effectiveness of
spirometry use, and asthma and COPD education in primary care setting on medication use among asthma and
COPD patients.
Methods: At the time of the intervention, the Lung Association of Saskatchewan has not assigned a control
group. Therefore we used a propensity score matching to create a control group using administrative health
databases spanning 6 years prior to the intervention. Using Saskatchewan administrative health databases, the
impacts of the intervention on use of asthma and COPD medications were estimated for one to four years after
the intervention using a difference in difference regression approach.
Results: The paper shows that overall medication use for the intervention group is higher than that of the
control group. On average, intervention group uses more asthma and COPD drugs. Within the asthma and COPD
drugs, this intervention creates a persistent effect over time in the form of higher utilization of chronic
management drugs equivalent to $157 and $195 in a given year during four years after the intervention.
Conclusions: The study suggests that effective patient education and increasing access to spirometry increases the
utilization of chronic disease management drugs among asthma and COPD patients. This type of interventions with
patient education focus has potential to save healthcare dollars by providing better disease management among this
patient group.
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Background
Adherence to medication is one of the critical determi-
nants of successful management of most chronic diseases
including asthma and chronic obstructive pulmonary dis-
ease (COPD). Studies, however, repeatedly emphasize that
non-adherence to medication, especially non-compliance
with self-management medication, is very common among
asthma and COPD patients [1–3]. As an attempt to im-
prove medication adherence, health outcome, and quality
of life, various interventions that target asthma and COPD
patients have been implemented [4–10]. Main goal of
these interventions was to educate patients about all
aspects of the disease, teach them coping skills to avoid
triggers, and to train the patients in medications with spe-
cific emphasis on doses, frequency of administration, and
possible side effects.
As shown in some studies recently reviewed in a
Cochrane review [11], patient education interventions
improve medication adherence, decrease emergency de-
partment (ED) visits, and hospital admissions. For in-
stance, Bruzzese et al. show that an education based
intervention implemented in a New York City school en-
vironment substantially reduces healthcare utilization
among adolescence [5]. The result of this randomized
control trial shows that the intervention participants ex-
perience a 28 % reduction in acute medical visits, a 49 %
reduction in ED visits, and a 76 % reduction in hospitaliza-
tions compared to adolescence receiving usual care. While
there are other studies reviewed in this Cochrane review
also showing similar results [4, 12], Farber and Oliveria
[10], and Bailey et al. [6] show that patient education pro-
grams targeting this patient group have no impact on
health care utilization measured by ED visits and
hospitalization. In addition to ED visits and rate of hospi-
talizations, Farber and Oliveria also examine the impact of
the intervention on medication [10]. They find that the
intervention group uses more (about one dispensation)
asthma controller medication compared to the control
group. There are also other studies indicating the impact
of patient education interventions on medication use for
management of asthma and COPD. In a school-based
intervention for urban adolescents, Bruzzese et al. [5] re-
port that the students in the intervention group relative to
the control group reported significantly greater use of con-
troller medication, and more confidence to manage their
asthma. Subsequent studies also report that patient educa-
tion program resulted in significantly better controller ad-
herence and long acting beta agonist adherence, improved
steroid inhaler compliance and higher cumulative control-
ler medication dose [4, 7, 9, 10, 13].
As a body of literature indicates, inappropriate or insuffi-
cient medications among patients with chronic conditions
can result in several negative consequences including treat-
ment failure, unnecessary and more intensified therapy,
costly diagnostic procedures and complications and
hospitalization. Hence effective asthma and COPD man-
agement with consistent use of self-management medica-
tions not only decreases emergency care, and unscheduled
doctor visits, but also improves quality of life, and reduces
productivity losses and disability leaves (for a review of this
literature see Nieuwlaat et al. [11]).
In an effort to improve asthma and COPD care and
health outcomes, the Lung Association of Saskatchewan
has implemented an intervention by providing access to
effective, and high-quality asthma and COPD education
for both patients and health care professionals along
with increasing access to spirometry to increase early
detection of these diseases. For this purpose, the Associ-
ation has placed spirometry and the Certified Respiratory
Educators (CREs) (certified healthcare professionals
with specific focus on asthma and COPD care) in
selected family physician offices in 2007. The objective
of the intervention was to educate patients in managing
their diseases.
By evaluating the impacts of the intervention con-
ducted by the Lung Association, our purpose in this
paper is to examine the effectiveness of spirometry use,
and asthma and COPD education in primary care setting
on medication use among asthma and COPD patients.
Our results show that overall medication use for the
intervention group is higher than that of the control
group. On average, the intervention group uses more
asthma and COPD drugs. Within the asthma and COPD
drugs, the intervention with its patient education focus
creates a persistent effect over time in the form of higher
utilization of chronic management drugs (i.e. inhaled
steroids (also known as inhaled corticosteroids), long
acting beta agonists) while it has no effect for the
utilization of other drugs.
Methods
Overview of the intervention
The main purpose of this intervention was to educate
patients on how to manage their diseases. In January
2006, the Lung Association has started a pilot interven-
tion by introducing CREs and spirometry to selected
family physician clinics in a medium size city in Canada.
In 2007, this intervention was fully implemented in fam-
ily physician offices who expressed interest in accessing
the education program for their patients with a diagnosis
of asthma and/or COPD. Physicians who participated in
the intervention recruited asthma and COPD patients to
the intervention if the patients (1) have asthma and/or
COPD and would highly benefit from the intervention,
or (2) require validation of their diagnosis, or (3) have
high risk of developing asthma and/or COPD. Appoint-
ments to see patients are made in the physicians’ clinics
for initial and follow-up consultations.
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Each patient visit started with spirometry administration
and continued with one hour patient education conducted
by the CREs. Each session included training and informa-
tion regarding the pathophysiology of the disease, medica-
tions and inhaler techniques, environmental control for
asthma, and coping skills. The intervention was patient
oriented with a special focus on the needs of the patients.
In order to meet the specific needs, it was tailored based
on the needs of a corresponding patient. For instance, if
the patient was a smoker, more time has been devoted to
explain smoking cessation programs.
At the end of each session, patients have consulted
with the physician for any change in medications and
an action plan afterwards. Office/phone follow-ups
within four weeks following the session were also
scheduled for all patients. While phone follow-ups were
around 15 min, office follow-ups were expected to last
for about an hour. However, the duration of office
follow-ups varied depending on the needs of the
patient. Similarly, patients also had a chance to consult
with the physician after the follow-up session. Certified
educators were available to meet with the patients
depending on the need and request by the patients after
the first follow-up.
Data source and intervention sample
Several data sets from the Saskatchewan health adminis-
trative databases were used for our analysis. An additional
file shows the description of each database in more detail
(see Appendix Table A.1. in Additional file 1). The out-
come variables (i.e. prescription drug cost and use) were
created using the Prescription Drug Plan Historical Claims
(PDP) that includes details on prescription drug related in-
formation such as quantity of drug dispensed, date of dis-
pensing, cost, type and name of the drugs with their drug
identification numbers. Additional databases such as the
Discharge Abstract Database (DAD) for patients’ hospitali-
zations, the Medical Services Billing Claims Data (MSB)
for the physician visits, the Personal Health Registration
System (PHRS) for patient demographics and location of
residence, and Vital Statistics Registry for death informa-
tion were utilized in this study.
All of the files can be linked with each other using the
encrypted unique identifier (encrypted provincial health
number) that are provided in each data set for all resi-
dents in the province. The Lung Association recorded
the provincial health number for intervention partici-
pants and this was converted to the encrypted form
using the same algorithm applied for encryption in all
other databases. The common identifier was then used
to obtain records for the intervention participants from
the Saskatchewan administrative health databases.
The ethics approval for this study has been obtained
from the University of Saskatchewan Biomedical Research
Ethics Board under Bio # 10–180. The patients gave free
and informed consent for linkage of data collected directly
from them (i.e., that they were participants in the CRE
program) and the administrative health data about their
utilization.
There were 271 patients participated to the interven-
tion in 2007. We restricted the intervention sample to
the patients with health care utilization data available
through the Saskatchewan administrative health data-
bases. Among 271 patients in the initial sample, we
dropped 28 patients due to missing de-identified health
number, and 13 patients with Registered Indian status
since there are no prescription drug data available for
them. We also excluded 15 patients as they did not live
in this health region during the pre-intervention period.
We also excluded 9 patients who died during the study
period. In addition, 13 patients who did not use any
physician services or were younger than seven in the
baseline year were also dropped. Finally, we further
excluded 8 patients for which no match were found in
our propensity score matching strategy. As a result, the
final intervention sample used in our intervention effect
estimations consists of 185 individuals1.
Outcome variables
By following Kuwornu et al. [14], and HQC [15], we
categorized the drugs under three groups (chronic
management, acute, and other unclassified drugs). We
grouped the drugs that are only used for chronic man-
agement (i.e. to control and improve symptoms) under
chronic management drug group (i.e. inhaled steroids
(also known as inhaled corticosteroids), long acting
beta agonists (LABA), anticholinergic, and xanthine).
The drugs that are only used for acute exacerbations
were identified under acute drugs (i.e. short-acting
beta-agonists (SABA), antibiotics). Following the study
conducted by HQC [15], other asthma drugs that are
not classified in chronic management or acute drugs by
Kuwornu and his colleagues [14] were grouped under
unclassified asthma drugs.
The cost of drugs is recorded in the databases in nom-
inal terms. In order to compute the real prescription
drug costs, we used 2002 as the base year, and adjusted
the cost using the Saskatchewan Consumer Price Index
for health and personal care commodity group.
Other variables
A rich set of variables including key demographic vari-
ables was used in the propensity score matching method
that is described in the next section. In order to capture
patient heterogeneity due to their health status, we used
comorbidity index based on the Charlson and Elixhauser
indexes [16, 17]. The list of binary variables indicating
the presence of corresponding comorbidities, and key
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demographic variables along with their descriptions are
presented in the additional file (see Appendix Tables
C.1-C.4 in Additional file 1).
Statistical analysis
Propensity score matching
In order to estimate the effects of the intervention on the
use of chronic disease management and acute drugs, one
needs to compare the outcomes between intervention par-
ticipants and comparable non-participants. Although we
have the intervention group exposed to the intervention,
no control group was assigned when the intervention was
conducted by the Lung Association. To deal with this
shortcoming, we constructed a control group using a pro-
pensity score (PS) matching strategy [18–20]. The purpose
of the matching is to identify individuals that have similar
characteristics to the intervention participants except for
the intervention status.
Before estimating the propensity scores based on a rich
set of covariates in a probit specification, we restricted the
potential control group using key characteristics of the
intervention group such as age and geographical location
and data availability prior to the intervention. For this pur-
pose, we restricted the potential control to the sample that
includes only individuals who used any physician services
during 2006, and who lived in the same health region with
the intervention participants prior to the implementation
of the intervention. We defined the period before the
intervention from April 2001 to December 2006. The time
period was chosen based on the availability of the data.
We dropped individuals who died at any time since
April 2001. We also constrained the sample to the indi-
viduals aged seven to ninety-six in 2006. Given that we
have no prescription drug information available for
people with Registered Indian status, we also dropped
them from the analysis.
Following this stratification, we estimated a probit
model to compute propensity scores. These scores were
estimated for each remaining individual in the risk set
using a probit model with a long list of baseline character-
istics including the baseline outcome variables as well as
health status measures such as comorbidity indicators for
19 conditions. These details are presented in the online
appendix to this paper (see Appendix Table B.1. in
Additional file 1). All statistical analysis outlined in this
and next sub-sections were employed using Stata (ver-
sion 12), and SAS (version 12) software programs.
There are various propensity score matching tech-
niques used in the literature (for a review see Austin
[21], Dehejia and Wahba [22]. The simplest one is the
nearest neighbor matching in which an intervention unit
is matched with a unit from the potential control that
has the closest propensity score to the corresponding
intervention unit. In the case of multiple matches, the
tie is broken by a random draw. Even though this
approach requires the propensity scores to be the closest
between the intervention and matched control units, it
has potential to create considerable bias. When we use it
with replacement, the nearest neighbor matching can
limit the number of matched controls which in turn may
result in small sample bias. If it is used without replace-
ment, then the quality of matched controls could be
poor due to possible large differences in the propensity
scores between the intervention unit, and the corre-
sponding matched control [22].
In an effort to deal with these shortcomings, caliper (ra-
dius) matching is used as an alternative in the literature.
This technique is simply an extension of the nearest
neighbor matching that is developed to avoid the small
sample bias, and the potential bias due to possible large
differences in the propensity scores. This approach con-
structs the matched control units whose propensity scores
are within a tolerated distance from the propensity score
of the respective intervention unit. Formally the matched
set M(i) for intervention unit i is defined as;
M ið Þ ¼ pjj jjpi − pjjj < r
n o
ð1Þ
where subscripts i and j stand for the intervention and
control units, respectively. The equation above denotes
that all control units with estimated propensity scores,
pj, fall within a radius r from the intervention unit i’s
propensity score, pi, are matched to the intervention
unit i.
In our study, we used a with replacement radius
matching using a radius of 0.005. This is the smallest
radius frequently used in the literature [23]. Given that
there can be multiple control units within the specified
radius, there are more than one match for each inter-
vention unit. In order to deal with unlimited number of
matches, we restricted the maximum number of
matched controls for each intervention unit at 10. All
potential controls with an estimated propensity score
falling within a specified radius defined above were
matched with the respective intervention unit. In the
case of multiple matches due to identical propensity
scores after nine successful matches, the tie was broken
by a random draw among the last group of matched
control units with identical propensity scores. We
removed the rest of potential control units if their pro-
pensity scores were away from the tolerated distance
from the propensity scores of any intervention units.
Following the approach described above, we per-
formed the matching and presented the distribution of
propensity scores for both groups in Fig. 1. The vertical
axis shows the probability of being in the intervention
group for the intervention and control groups whereas
the horizontal axis displays the observation identifier
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number for the intervention units. As there are multiple
matches for individuals in the intervention group, the
mean propensity scores of matched controls for the cor-
responding intervention unit, and the propensity score
of each intervention unit are illustrated in the figure.
The figure shows that the propensity scores for both
groups are almost identical implying that both groups
have the same propensity score distribution.
In order to assess the quality of matching based on
observed characteristics as well as to understand the
baseline values for outcome variables, we presented the
baseline characteristics between the control and inter-
vention groups. Table 1 shows the summary statistics for
main variables with a mean difference test between the
groups. As indicated in the table, the two groups have
similar characteristics at baseline; the mean differences
for each covariate between two groups are not statisti-
cally significant at 5 % significance level.
Regression framework to estimate the intervention effect
In order to estimate the effect of the intervention on use
of chronic management asthma and COPD medications,
we used a combined matching and a difference in differ-
ence (DID) regression approach rather than a matching
estimator alone to estimate the intervention effect. An
advantage of the combined matching-DID approach is
that it relies on relatively weaker assumptions compared
to the matching estimators alone. In the case of match-
ing estimators, the estimated intervention effect relies
on the independence assumption between the exposure
to the intervention and potential health outcome upon
controlling the relevant covariates [24]. One way to vio-
late this assumption would be through unobservable fac-
tors affecting the selection to the intervention that in
turn affects health outcome. The combined matching-
DID approach removes any remaining, even after match-
ing, time-invariant systematic differences between the
intervention and control units. Although the combined
approach eliminates any time invariant unobserved dif-
ferences, it cannot provide a solution to any bias due to
a change in health status for either group after the
matching. One important health status indicator would
be the new health conditions and comorbidities that are
developed after the matching. With a combined
matching-DID approach, we controlled for several
comorbidities developed any time after the baseline as
defined below:
yi ¼ αþ βIi þ γDi þ δxi þ εi ð2Þ
where subscript i stands for individuals who are either in
intervention or control groups.
The dependent variable, yi = Yi1 − Yi0, denotes the
change in outcome variable Y before and after the inter-
vention. In order to capture time variant differences
between the intervention and control units, we used
changes in the number of chest imaging services provided,
physician consultation via telephone, non-clinical phys-
ician services (i.e. health teaching/counseling regarding
patient’s treatment), and physician services received with
provisional codes before and after the intervention. In
addition, we used a matrix of indicator variables, Di, for
Fig. 1 Distribution of propensity scores for intervention and control groups
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several new conditions and comorbidities developed any
time after the baseline.
In order to determine the intervention effects, we are
specifically interested in estimating the coefficient of the
indicator variable, Ii, that identifies the intervention
group. As a result, the model above was estimated separ-
ately for each year after the intervention to obtain one
to four year intervention effects. We summarized main
results for the intervention effect in the next section.
The full results for each outcome variable are presented
in the additional file (see Appendix Tables D.1-D.4, and
G.1-G.4 presented in Additional file 1).
Results
We examined the intervention effect on cost and dispen-
sation of medications by type of the prescription drugs.
For each outcome variable, we estimated model (2) for
each year in order to identify the intervention effect in
the corresponding year. Table 2 presents a summary
result for the cost of prescription drugs within one to
four years after the intervention while Table 3 presents
the same information for drug dispensations.
Each column in Table 2 presents the intervention
effect for the corresponding year. As shown in the table,
overall drug cost for the intervention group is higher
than that of the control group. On average, intervention
group spends more on prescription drugs primarily due
Table 2 Summary results for the intervention effect on annual
cost of prescription drugs
2008 2009 2010 2011
Asthma/
COPD drugs




164.5 (0.00) 178.5 (0.00) 195.5 (0.00) 157.1 (0.00)
Asthma/COPD
acute drugs
−6.45 (0.41) −10.4 (0.18) −6.09 (0.48) −8.5 (0.40)
Other asthma
drugs (unclassified)
34.6 (0.06) 24.1 (0.18) 15.5 (0.35) 8.03 (0.60)
Other drugs −2.6 (0.97) 51.4 (0.53) 168.2 (0.15) 109.1 (0.38)
All drugs 190.0 (0.04) 243.6 (0.02) 373.2 (0.01) 265.7 (0.06)
Note: The numbers in parentheses show the p-values for the statistical
significance of the estimated coefficient for the intervention effect. P-values
for statistically significant results are shown in bold
Table 1 Baseline comparisons for main outcome variables
Intervention Control p-values for mean
difference testMean SD Mean SD
Physician services
Cost (average cost in dollars/year) 559 550 549 670 0.83
Prescription drug cost (average cost in dollars/year)
Asthma/COPD drugs 228 436 170 416 0.08
Asthma/COPD chronic management 149 354 110 335 0.13
Asthma/COPD acute drugs 62 104 50 115 0.18
Asthma drugs (unclassified) 17 123 10 65 0.23
Other drugs 841 1331 877 2789 0.86
Total drugs 1069 1490 1047 2840 0.92
Prescription drug dispensations (average count/year)
Asthma/COPD drugs 5.2 7.44 4.1 7.09 0.06
Asthma/COPD chronic management 2.0 4.59 1.4 3.84 0.06
Asthma/COPD acute drugs 2.9 3.82 2.5 4.24 0.18
Asthma drugs (unclassified) 0.27 1.38 0.20 1.07 0.41
Other drugs 19.6 24.67 17.8 25.81 0.36
Total drugs 24.8 27.23 21.9 27.84 0.18
Hospital services (average count/year)
Inpatient admission 0.10 0.36 0.08 0.35 0.63
Length of stay 0.59 2.44 0.39 2.46 0.29
Note: The mean shows the annual average for each variable. SD stands for standard deviations. The last column presents the p-values for the mean difference test
between control and intervention groups. Costs for physician services and prescription drugs are measured in current dollars while drug dispensations and
hospital services are measured in average annual counts of dispensations or encounters.
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to asthma and COPD related drugs. However, there is
no difference in the use of acute care asthma and COPD
drugs. This change is primarily driven by the chronic
management drugs.
The intervention creates a persistent effect over time
in the form of higher utilization of chronic management
drugs. In particular, Table 2 shows that the effect on the
annual cost of chronic management drugs within one to
four years following the intervention is between $157
and $195. As compared to the cost for chronic manage-
ment drugs at the baseline, this effect is quite substantial.
It implies that the intervention increases the cost by more
than 100 % of the baseline cost for chronic management
drugs of the intervention group.
We observe the same pattern over the same time
period when we assess the dispensation of chronic man-
agement drugs in average number of annual prescription
filled. As shown in Table 3, the intervention increases
the dispensation of chronic management drugs. The
effect varies from 1.4 to 1.6 prescription filled in a given
year. This overall effect on chronic management drugs
clearly indicates that the use of chronic management
medications substantially increases with the intervention
even four years after the intervention. For any other
types of drugs, there is no evidence that the intervention
has any impact on cost or number of prescription drug
utilization.
Discussions
Administrative health databases provide a unique oppor-
tunity to follow patients across multiple years and
observe their drug dispensations. By comparing the
intervention participants with a comparable control
group we examined the impact of intervention on medi-
cation use, and other health care service utilization.
Our results suggest that intervention participants have
consistently used more chronic management drugs dur-
ing four consecutive years following the intervention.
This finding related to the long-term sustainability of
the intervention is an important contribution to the
literature as previous studies reported that the initial
increase in the use of chronic management drugs started
to decrease after the active intervention period [4].
While we showed that intervention increases the use of
chronic disease management drugs, it does not have any
statistically significant effect on number of hospitaliza-
tions, length of hospital stays, and cost of physician
visits. We presented a summary table showing these
additional findings (see Appendix: Table 4). This implies
that the intervention may generate saving since it is ex-
pected that patients who can manage their diseases bet-
ter, are more likely to require fewer resources when
hospitalized. Given that an average cost of an inpatient
visit is $2,938 for asthma and $6,514 for COPD patients
[25], even a small difference in required resources dur-
ing inpatient treatment generates substantial net savings
for the healthcare system.
As indicated earlier, a body of literature shows that
better asthma and COPD management reduces unsched-
uled health care use [5, 13, 26]. Therefore, the patient
education intervention studied in this paper may also
generate an additional saving by reducing emergency
care visits. The Canadian Institute for Health Informa-
tion (CIHI) estimates that the average cost for a single
asthma related emergency department visit is $205 while
the average cost of a COPD related visit is $275 [25].
Our results suggest that the incremental cost of the
intervention in the form of higher utilization of chronic
management drugs is lower than the average cost of one
emergency visit for this patient group. This implies that
the intervention would create net saving if, on average,
less than one emergency department visit per patient is
avoided even if it has no impact on other health out-
comes. However, emergency department data are not
available for this study to directly measure whether
emergency utilization decreases. Due to limitations in
data availability for emergency care visits, and intensity
of inpatient care for the study participants, we cannot
examine these issues. These additional questions deserve
further research.
In addition to the limitation mentioned above, there
are other shortcomings of administrative health data-
bases. For instance completeness and quality of admi-
nistrative databases can be considered as another
limitation. In our case, drugs administered in hospitals
and over the counter purchases are not captured in the
PDP database. As smoking cessation drugs are available
over the counter, we are unable to fully capture the im-
pact of these drugs on patient behavior regarding the
Table 3 Summary results for the intervention effect on drug
dispensations in counts
2008 2009 2010 2011
Asthma/
COPD drugs
2.12 (0.00) 1.95 (0.00) 2.01 (0.00) 1.45 (0.03)
Asthma/COPD
chronic management
1.52 (0.00) 1.66 (0.00) 1.62 (0.00) 1.45 (0.00)
Asthma/COPD
acute drugs
0.03 (0.91) −0.12 (0.69) 0.11 (0.74) −0.17 (0.60)
Other asthma drugs
(unclassified)
0.58 (0.02) 0.41 (0.06) 0.27 (0.18) 0.17 (0.37)
Other drugs −0.73 (0.54) 0.78 (0.55) 0.49 (0.71) 1.79 (0.24)
All drugs 1.39 (0.34) 2.73 (0.09) 2.50 (0.14) 3.23 (0.09)
Note: The numbers in parentheses show the p-values for the statistical
significance of the estimated coefficient for the intervention effect. P-values
for statistically significant results are shown in bold
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use of other asthma and COPD drugs. These limitations
need to be taken into consideration when interpreting
the results documented in this paper.
Conclusion
In this paper, we examined the effects of Lung Association’s
intervention on asthma and COPD medications using
propensity score matching and regression analysis. Our
results show that the intervention improves medication
use, especially for those that are used for management
of asthma and COPD. The effect is significant and per-
sistent during the study period covering four years after
the intervention. However, there is no observed inter-
vention effect on use of asthma and COPD acute care
drugs, other asthma drugs, or utilization of other drugs
which are not related to asthma and COPD. Our main
result shows that the intervention increases the chronic
management drug costs by about $157 to $195 in any
year during the study period. The same pattern for
dispensations of chronic management drugs were also
observed in this study. Based on our findings, we con-
clude that an education program for asthma and COPD
patients has potential to improve patients’ health out-
come by increasing the use of chronic management
medications.
Endnote
1At the time of the intervention, the researchers of this
paper were not part of the team conducting the inter-
vention. Therefore they have not performed any power
analysis to determine the sample size.
Appendix
Our additional results indicate that the intervention does
not have any statistically significant effect on number of
hospitalizations, length of hospital stays, and cost of
physician visits. These findings are summarized in Table
4 below.
Additional file
Additional file 1: There is an online appendix uploaded in pdf
format with a file name ofHSR_Online_appendix. It presents the full
results from our empirical analysis including a brief description of
databases used in this paper. (PDF 856 kb)
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